Rare hemorrhagic disorder due to an acquired coagulation factor defect

Rare hemorrhagic disorder due to an acquired coagulation factor defect is a group of bleeding disorders in which the body develops an abnormality in one or more coagulation (clotting) factors that is not inherited but rather acquired during a person's lifetime. Unlike inherited bleeding disorders such as hemophilia, these conditions arise due to the development of autoantibodies (inhibitors) against specific clotting factors, or through other acquired mechanisms such as consumption, decreased production, or increased clearance of coagulation factors. The most well-known example in this category is acquired hemophilia A, caused by autoantibodies against factor VIII, but acquired deficiencies of other factors (such as factor V, factor X, factor XIII, prothrombin, and others) have also been described. These disorders primarily affect the hematologic system and can manifest with a wide range of bleeding symptoms, including spontaneous bruising, soft tissue hemorrhage, mucosal bleeding (such as gastrointestinal or genitourinary bleeding), prolonged bleeding after surgery or trauma, and in severe cases, life-threatening hemorrhage. Unlike congenital hemophilia, joint bleeding (hemarthrosis) is relatively uncommon. The condition can occur in association with autoimmune diseases, malignancies, pregnancy, certain medications, or may be idiopathic with no identifiable underlying cause. Diagnosis involves laboratory evaluation showing prolonged clotting times (such as aPTT or PT depending on the factor involved), reduced levels of specific coagulation factors, and often the detection of inhibitory antibodies through mixing studies and Bethesda assays. Treatment typically involves two strategies: controlling acute bleeding episodes using bypassing agents (such as activated prothrombin complex concentrates or recombinant activated factor VII) or replacement therapy, and eradicating the inhibitor through immunosuppressive therapy, which may include corticosteroids, cyclophosphamide, rituximab, or other immunosuppressive agents. Early recognition and prompt treatment are critical, as mortality rates can be significant if the condition is not managed appropriately.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Rare hemorrhagic disorder due to an acquired coagulation factor defect